Pneumocystis jirovecii is an opportunistic fungus causing Pneumocystis pneumonia primarily in immunosuppressed patients. However, immunocompetent individuals may become colonized and, as asymptomatic carriers, serve as reservoirs of the pathogen. Moreover, these asymptomatic carriers are at higher risk of developing pneumonia if favorable conditions occur. This study aimed to determine the prevalence of P. jirovecii in patients with various pulmonary diseases and to characterize the genetic diversity of organisms circulating in the studied population. Bronchial washing specimens from 105 patients were tested for presence of P. jirovecii using nested polymerase chain reaction (PCR) targeting the mtLSU rRNA gene, as well as immunofluorescence microscopy. Multilocus sequence typing involving analysis of three locimtLSU rRNA, CYB, and SOD-was used for genotyping analysis. P. jirovecii DNA was detected in 17 (16.2%) patients. Amplification of the SOD locus was successful only in five cases (29.4% of the positive patients), while mtLSU rRNA and CYB were genotyped in all positive samples. Therefore, combined genotypes were identified based only on mtLSU rRNA and CYB loci. Eight different genotypes were identified, with Pj 1 and Pj 2 being the most prevalent (29.4% of patients each). There was no statistical correlation between these genotypes and demographic or clinical data; however, we found that infection with mutant CYB strains occurred only in patients diagnosed with lung cancer. Of the potential predictors examined, only immunosuppressive treatment was significantly associated with colonization. In conclusion, patients with various C The Author(s)
Introduction
Pneumocystis jirovecii, formerly Pneumocystis carinii f. sp. hominis, is a unicellular fungal species occurring in human lungs. 1 Since Pneumocystis is an opportunistic pathogen, its infection may lead to the development of Pneumocystis pneumonia (PcP) primarily in immunocompromised individuals, who represent the main group at risk. 2 In turn, its presence in immunocompetent people usually does not trigger any clinical signs or symptoms. It may, however, persist as an asymptomatic carriage, defined as colonization. 3 This phenomenon, in contrast to active infection, is characterized by the low fungal burden and does not cause the disease in the carrier. Pneumocystis presence in a biological specimen from a person without clinical symptoms of pneumonia or related radiological signs may be confirmed by molecular methods but not necessarily by microscopic examination, due to the low fungal burden. 4 It is assumed that the concept of colonization is used whenever P. jirovecii DNA is detected in specimens taken from asymptomatic patients at risk of infection. 5 It has been shown that colonization occurs among individuals with pulmonary diseases, with a frequency depending on the geographical location and type of respiratory diagnosis. 6, 7 The causal link, however, has not been elucidated and requires further investigation. On the one hand, even asymptomatic presence of the pathogen in the lungs may induce a host inflammatory response and lung damage, thereby potentially contributing to the infection of other pathogens or development of chronic lung diseases. 7 On the other hand, pulmonary lesions and lung tissue damage induced by preexisting respiratory ailments might favor Pneumocystis colonization by facilitating its pulmonary involvement. 8 The research on Pneumocystis has been hindered due to the lack of appropriate systems for in vitro culture of this organism. 9 Therefore, molecular methods have been applied for the investigation of Pneumocystis transmission and diversity. 10 Multilocus typing is considered to be the gold standard for such evaluation, as it involves analysis of two or more loci, thereby providing higher sensitivity and accuracy than single locus typing. 11 Maitte et al. 12 proposed a simplified approach involving analysis of three loci: mitochondrial large subunit (mtLSU) rRNA, cytochrome b (CYB), and superoxide dismutase (SOD). Such a scheme provides a sufficiently high discriminatory power for genetic diversity analysis, required for preliminary epidemiological investigation of Pneumocystis occurrence. The incidence of particular genotypes in various populations may indeed be influenced by the underlying disease, immunosuppressive treatment, climatic and geographical factors as well as divergent application of PcP prophylaxis in different health care systems. 13 Owing to the arguments presented above, exploration of P. jirovecii epidemiology and transmission in specific populations is an important issue. However, to date they have not been sufficiently elucidated in Poland, so there are few data available on the prevalence of Pneumocystis and epidemiological profiles occurring in the country (and particularly in Lower Silesia). 14 Therefore, the main objectives of the present study were to: (i) determine the prevalence of P. jirovecii among patients with a variety of respiratory diseases; and (ii) characterize potential associations between demographic and clinical data and distribution of the multilocus genotypes (MLGs), combining three independent polymorphic loci: mtLSU rRNA, CYB, and SOD.
Methods

Patients and specimens
The study involved 105 human immunodeficiency virus (HIV)-negative patients who had been receiving care at the Department of Pulmonology and Lung Cancer of Wroclaw Medical University (Wroclaw, Poland) between July 2015 and September 2016. All of these patients required flexible bronchoscopy as part of their diagnostic management for possible respiratory disease. During the procedure, the bronchoscope was introduced into the main bronchi and 30-60 ml of the warmed saline (room temperature) was instilled through the working channel into the airways. The bronchial washing (BW) was recovered via a suction channel into a suitable receptacle. Fresh BW samples were centrifuged, and the sediment was resuspended in the remnant of supernatant. In sum, 20 μl of cell pellets were used to smear slides. High quality acetone was used to fix the slides to be stained. The remaining amount was frozen at −20 • C for maximum 2 weeks without preservatives before molecular analysis. Since BW collection is an invasive method, samples were taken only once from each patient. Informed consent, approved by the Human Research Ethics Committee of Wroclaw Medical University according to agreement no. KB648/2014, was obtained from all individual participants included in the study.
Detection of P. jirovecii
After homogenization by bead disruption using a Precellys24 Instrument (Bertin Technologies, France) and digestion with proteinase K at 56
• C for 1 hour, total DNA was extracted using QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany). The detection of P. jirovecii organisms was performed using a nested polymerase chain reaction (PCR) protocol amplifying the mtLSU rRNA gene using Taq polymerase, as described previously, 15, 16 with a sample of human-derived P. jirovecii DNA used as a positive control in each experiment. Molecular examination was repeated two or three times for each sample. Additionally, indirect immunofluorescence (IF) assay (MonoFluo kit P. jirovecii; Bio-Rad) was applied. Two to three slides were prepared for each patient sample. They were examined with a fluorescence microscope, using 20× and 40× dry objectives. The entire stained region was screened if no P. jirovecii was seen. It enabled assessment of fungal burden by scoring the total number of cysts observed. 17 
Case definition
The diagnosis of PcP was made on the basis of specific clinical symptoms of pneumonia (low-grade fever, dyspnea, unproductive cough) and/or typical radiologic findings (bilateral ground glass opacity on chest radiography or chest computed tomography), confirmed by microscopic and molecular examination of BW specimens. A P. jiroveciicolonized patient was defined as an individual without symptoms or thoracic radiography signs of PcP, from whom a BW specimen contained P. jirovecii DNA detectable by nested PCR and was or was not positive by IF assay. An IF sample was assumed to be positive if five or more fluorescing cysts or clusters of cysts were identified; one to five fluorescing cysts recorded on a whole slide were interpreted as an equivocal result, suggesting a colonization case. 17, 18 When no cysts were identified on a whole slide, an IF sample was considered negative.
Multilocus typing
All positive products of nested PCR amplifying the mtLSU rRNA locus were sequenced to detect polymorphisms at two informative positions (85 and 248). Bands of the expected size (260 bp) were visualized by agarose gel electrophoresis and purified with the Zymoclean Gel DNA Recovery Kit (Zymo Research, Irvine, CA, USA).
Products were sequenced bi-directionally by a company offering this service commercially. 
Results
P. jirovecii prevalence and patients' characteristics
The mean age of all patients (n = 105, including 70 males, 35 females) was 62 ± 12.7 years, range 27-87 years. None of the examined patients was subjected to anti-Pneumocystis prophylaxis. DNA of P. jirovecii was detected in 17 of the 105 (16.2%) subjects studied. Moreover, eight out of these 17 patients (47%) were confirmed as Pneumocystis-positive by IF staining as well. However, the low number of cysts (less than five) observed in all these cases and the lack of clinical signs and symptoms compatible with PcP (except for one case of dyspnea) suggested colonization. Since none of the patients included in this study was diagnosed with PcP, no specific treatment was prescribed and their further outcome was not followed after specimens' collection. Basic characteristics of P. jirovecii-positive and -negative patients, underlying diseases potentially associated with Pneumocystis colonization, as well as immunosuppressive regimens are listed in Table 1 . There were no significant differences in sex, age, or the frequency of certain underlying respiratory diseases. The only one statistically significant correlation was observed between the application of immunosuppressive agents (cytotoxic drugs or steroids) and Pneumocystis colonization (P = .016, Fisher's exact test).
Multilocus typing
Both mtLSU rRNA and CYB genes were amplified successfully in all analyzed specimens, whereas the SOD gene was amplified only in five of the 17 (29.4%) P. jirovecii-positive patients (Table 2) . Therefore, genotyping was performed combining mtLSU rRNA and CYB types. As a result, eight genotypes were determined ( Table 3 ). The two most common were Pj 1 (comprising wild-type versions of both genotypes) and Pj 2, found in five specimens each (29.4%). For mtLSU rRNA, three of the five previously described genotypes were identified: genotype 2 occurred in eight patients' samples (47%), while genotypes 1 and 3 were detected in five (29.5%) and four (23.5%) a For further details, see Table 2 .
patients' samples, respectively. Mutant CYB genotypes were identified in five samples (29.4%). These included isolates with genotypes CYB 2, 5, 6, 7, and 8, observed in one case each.
There was no statistically significant correlation between MLG distribution and patients' underlying conditions or immune status, or the season in which infection occurred. However, taking into account single genotypes, we observed that infection with mutant CYB strains occurred in patients diagnosed only with lung cancer (P = .029, Fisher's exact test).
Discussion
Pneumocystis infection is considered mainly in terms of HIV diagnosis. Nevertheless, other groups of patients with impaired immunity, such as organ transplant recipients and oncologically treated individuals, are also at high risk of being infected with Pneumocystis and developing PcP. 22 Moreover, growing evidence proves that patients with various lung diseases constitute a group susceptible to Pneumocystis infection as well. 6 Its prevalence among this group of patients varies between different areas, depending on epidemiological factors, such as climatic characteristics of a specific geographical location. 23 In Europe, the level of
Pneumocystis colonization among non-HIV-infected patients with lung diseases varies from 2.5% in Italy, 24 4.4%
in Denmark, 25 12.5% in France, 26 24 .4% in Portugal, 27 up to 27.1% in Spain. 28 Our findings (16.2%) correlate with published data from other European countries located in a similar climate zone: Germany (19%) 29 and the United Kingdom (18%). 30 Despite being asymptomatic, Pneumocystis colonization remains an epidemiological problem. First of all, not only may colonized individuals transmit the pathogen to other people, 31 but also, if the immune status of the carrier deteriorates, colonization may develop into pneumonia. Second, application of anti-Pneumocystis prophylaxis in colonized individuals is difficult to implement and could lead to the selection of drug-resistant strains. 32 Finally, presence of the pathogen in the lungs may induce a host inflammatory response and tissue damage, which in turn can lead to the development of pulmonary diseases. 6 In fact, it has been proposed that high rates of colonization may be associated with specific chronic lung diseases (interstitial lung diseases, COPD or lung cancer). 7, 8, 33, 34 However, there was no significant difference in the frequency of certain disease entities between Pneumocystis-positive and -negative individuals in our study. These data are not consistent with previous reports, 6-8 which may be explained by the influence of other factors, such as those associated with geographical location, on Pneumocystis prevalence in patients at risk. 35 Also, we observed a statistically significant correlation between the application of immunosuppressive agents and presence of P. jirovecii in BW specimens. Since generally the immunosuppressive treatment increases susceptibility to colonization of this opportunistic pathogen regardless of the type of basic disease entity, such a correlation seems to be predictable. 4 Our results confirm that, similarly as in organ transplant recipients and other groups at risk, the inclusion of immunosuppressive treatment may further support the colonization of Pneumocystis in the lungs and PcP should be considered as a possible complication in these individuals. 36, 37 Besides their effect on the prevalence of Pneumocystis, the above factors may also be associated with the occurrence of genetic variations among circulating Pneumocystis strains. 13 The most robust information can be achieved by genotyping more than one locus simultaneously. The mtLSU rRNA gene, involved in basic mechanisms of translation by providing activity of peptidyl transferase to the mitochondrial ribosome, 38 has been widely used for genetic characterization of P. jirovecii isolates from different geographic areas. 13, 20, 21, 28 Sequencing of this locus in our studies revealed the presence of three different genotypes, with genotype 2 observed most frequently. This genotype was also the most common among patients suspected of pulmonary infection residing in Rome, Italy. 39 In contrast, genotype 1 is the most frequent among HIV-positive and -negative patients from other European countries, such as Portugal, Spain, or France. 13, 26 These differences in genotype distribution support the assumption of the epidemiological impact on circulation of particular Pneumocystis strains in the designated areas. 13 The SOD gene encodes an enzyme responsible for protection against free oxygen radicals, capable of causing harmful oxidative stress, to which Pneumocystis is particularly exposed due to its pulmonary tropism. 40 In the present study, successful amplification of this locus occurred in only 29.4% of cases. This is probably associated with the fact that the SOD gene occurs in a single copy in the Pneumocystis genome, so the efficiency of its amplification is relatively low. 12, 20 This is particularly problematic in the case of a low fungal burden, characteristic for colonized patients included in this study. Nevertheless, out of five previously described genotypes, we detected only SOD 1 and SOD 2, which are also the ones most often found in France, Portugal, and Cuba. 12, 19, 20 Cytochrome b, encoded by CYB gene, is a target for atovaquone, a drug used in prophylaxis for Pneumocystis infection. It has been shown that the occurrence of polymorphisms within the CYB locus may be associated with previous exposure to atovaquone 41 or even lead to drug resistance. 32 However, nearly one-third of patients enrolled in this study were infected with organisms carrying polymorphisms at the CYB locus, even though none of them was subjected to any Pneumocystis prophylaxis regimen, suggesting that alterations in this gene might be induced by other factors as well. This is in agreement with the fact that the non-synonymous mutations detected in our samples (genotypes CYB 2 and CYB 7, Table 2 ) do not concern the atovaquone-binding site of cytochrome b. 19 Interestingly, all samples with identified CYB versions differing from the wild type were collected solely from patients diagnosed with lung cancer. A possible explanation is that these individuals are characterized by conditions promoting colonization of P. jirovecii organisms with certain genetic variations. Similar findings concerning the occurrence of specific genotypes in a particular group of patients have been described for mtLSU rRNA genotypes when comparing non-HIVinfected and HIV-infected individuals. 28, 42 Another reason for such variability may be the influence of some agents used in treatment of patients with lung cancer on promoting the development of such polymorphisms. Taken together, these reports suggest that different underlying conditions might determine the specific pattern of genotype distribution. This assumption, however, should be taken with caution. The group of patients included in this study is very heterogeneous and patients with lung cancer constitute the majority. Therefore, even though statistically significant, the associations of mutations in a single genotype may be distorted by the unbalanced ratio of patients. Further research with the respective demographic and clinical information should be conducted in order to clarify these associations, preferably in a study including a larger sample. As a result of this study eight genotypes based on mtLSU rRNA and CYB loci were identified using multilocus genotyping methodology. Among them the most prevalent were Pj 1 and Pj 2, occurring in 29.4% of patients each. Other genotypes were identified in individual patients only (except Pj 3, found in two cases), which may suggest that inter-human transmission is the main source of Pneumocystis infection, involving strains with genetic alterations, and appearance of mutant genotypes may result from specific patient conditions and/or selective pressure of treatment. This is of particular importance for immunosuppressed patients, the main group at risk of PcP, since certain mutations may be associated with drug resistance or specific clinical parameters of infection. 43 In conclusion, the prevalence of 16.2% observed in this study testifies to the fact that patients with various pulmonary diseases are at risk of Pneumocystis colonization. Apart from its potential role in the development or maintenance of chronic lung diseases, investigation on Pneumocystis prevalence is also important due to the fact that carriers may constitute a reservoir of this pathogen, including resistant forms. Circulating strains may in fact comprise genetic variations, detected even among individuals not exposed to known selective pressure, providing evidence for inter-human transmission as the main source of infection. Finally, our results suggest that if asymptomatic Pneumocystis infection occurs among non-HIV-infected individuals, it is likely that HIV-infected patients remain at risk of colonization, the former being a possible source of infection. In this respect, the significance of colonization in an epidemiological context requires further thorough analysis. To our knowledge, this is the first study in Poland concerning P. jirovecii genetic diversity and the prevalence of this organism among non-HIV-infected patients with a variety of pulmonary diseases. 
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